期刊
PHARMACOLOGY & THERAPEUTICS
卷 90, 期 2-3, 页码 105-156出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/S0163-7258(01)00132-2
关键词
melanoma; leukemia; interferons; melanocyte development; high-throughput screen; mda genes
资金
- NCI NIH HHS [CA74468, CA72955, CA63753, CA 83705, CA35675] Funding Source: Medline
- NIDDK NIH HHS [DK52825] Funding Source: Medline
- NINDS NIH HHS [NS31492] Funding Source: Medline
Current cancer therapies are highly toxic and often nonspecific. A potentially less toxic approach to treating this prevalent disease employs agents that modify cancer cell differentiation, termed 'differentiation therapy.' This approach is based on the tacit assumption that many neoplastic cell types exhibit reversible defects in differentiation, which upon appropriate treatment, results in tumor reprogramming and a concomitant loss in proliferative capacity and induction of terminal differentiation or apoptosis (programmed cell death). Laboratory studies that focus on elucidating mechanisms of action are demonstrating the effectiveness of 'differentiation therapy,' which is now beginning to show translational promise in the clinical setting. (C) 2001 Elsevier Science Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据